Royalty Pharma Plc (RPRX)vsVerizon Communications Inc (VZ)
RPRX
Royalty Pharma Plc
$54.48
+2.35%
HEALTHCARE · Cap: $31.08B
VZ
Verizon Communications Inc
$48.35
-0.42%
COMMUNICATION SERVICES · Cap: $197.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Verizon Communications Inc generates 5601% more annual revenue ($139.15B vs $2.44B). RPRX leads profitability with a 33.9% profit margin vs 12.5%. VZ appears more attractively valued with a PEG of 0.89. VZ earns a higher WallStSmart Score of 68/100 (B-).
RPRX
Buy65
out of 100
Grade: C+
VZ
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.2%
Fair Value
$34.23
Current Price
$54.48
$20.25 premium
Margin of Safety
-31.3%
Fair Value
$36.74
Current Price
$48.35
$11.61 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Attractively priced relative to earnings
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 25.2%
Generating 3.8B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
2.9% revenue growth
4.3% earnings growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bull Case : VZ
The strongest argument for VZ centers on P/E Ratio, Market Cap, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Bear Case : VZ
The primary concerns for VZ are Revenue Growth, EPS Growth, Debt/Equity. Debt-to-equity of 1.90 is elevated, increasing financial risk.
Key Dynamics to Monitor
RPRX profiles as a mature stock while VZ is a value play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.40 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
VZ generates stronger free cash flow (3.8B), providing more financial flexibility.
Bottom Line
VZ scores higher overall (68/100 vs 65/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Verizon Communications Inc
COMMUNICATION SERVICES · TELECOM SERVICES · USA
Verizon Communications Inc. is an American multinational telecommunications conglomerate and a corporate component of the Dow Jones Industrial Average. The company is headquartered at 1095 Avenue of the Americas in Midtown Manhattan, New York City, but is incorporated in Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?